Arca
Skip to content

Vomiting

Drug research and approvals for vomiting: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 116 studies of vomiting are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 116
  • Trials authorized in Canada: 14
  • FDA orphan approvals: 0
  • EU medicines: 6

Recruiting Now

Newest start dates first, of 116 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

13 approved, 8 in phase 3, 4 in phase 2; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Ondansetron, Aprepitant, Metoclopramide, Granisetron, Meclizine, Palonosetron, Fosaprepitant, Valproic acid, Diphenhydramine, Dronabinol, Cromolyn, Rolapitant, Fosnetupitant

Dexamethasone
Phase 3 Glucocorticoid receptor agonist
Casopitant
Phase 3 Neurokinin 1 receptor antagonist
Acetaminophen
Phase 3 Cyclooxygenase inhibitor
Hydrocodone
Phase 3 Opioid receptors; mu/kappa/delta agonist
Promethazine
Phase 3 Histamine H1 receptor antagonist
Azithromycin
Phase 3 Bacterial 70S ribosome inhibitor
Gabapentin
Phase 3 Voltage-gated calcium channel modulator
Ramosetron
Phase 3 Serotonin 3 (5-HT3) receptor antagonist
Olanzapine
Phase 2 Serotonin 2a (5-HT2a) receptor antagonist
Capsaicin
Phase 2 Vanilloid receptor opener
Pyridoxine
Phase 2 Supplement

How Its Trials Ended

1,067 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 230 whose ending is known, 48% met their primary endpoint, 8% missed it and 44% stopped early.

  • Completed, result not reported52950%
  • Status unknown16816%
  • Ongoing14013%
  • Met its primary endpoint11010%
  • Stopped: other or unclear585%
  • Stopped: enrollment or feasibility313%
  • Missed its primary endpoint192%
  • Stopped: lack of efficacy61%
  • Stopped: sponsor or business decision40%
  • Stopped: safety10%
  • Stopped: funding10%

Trials Authorized in Canada

The 10 newest of 14; search them all in Canada trials
Apr 15, 2026Prophylaxis for emetogenic radiotherapy with akynzeo (pret)Netupitant-palonosetronUniversity Health NetworkPending
Mar 30, 2026Effect of aprepitant on post-operative nausea and vomiting in otologic surgery: a pilot randomized controlled trialAprepitantCiusss Du Centre-Ouest-De-L’Ile-De-Montreal, Institution Of Santé QuebecPending
Dec 3, 2025Adding aprepitant to a multimodal strategy for preventing postoperative nausea and vomiting in high-risk patients undergoing outpatient surgeryAprepitantSanté QuéBec¿- Centre Hospitalier De L’Université De MontréAlOngoing
Dec 7, 2023A randomized controlled trial comparing aprepitant to standard of care for postoperative nausea and vomiting prophylaxis in children undergoing scoliosis…AprepitantDr. Mathew KiberdOngoing
Jun 1, 2023Administration of aprepitant for the prevention of nausea and vomiting in pregnant women undergoingAprepitantSanté QuéBec¿- Centre Hospitalier De L’Université De MontréAlPending
Feb 22, 2023Randomized, double-blind, phase 2/3 study of iv amisulpride as prevention of post-operative nausea and vomiting in pediatric patientsAmisulpride (APD421) / ondansetronAcacia PharmaOngoing
Jan 11, 2017Randomized controlled trial of olanzapine for the control of chemotherapy-induced vomiting in children receiving chemotherapy for hematopoietic stem cell…OlanzapineThe Hospital For Sick ChildrenOngoing
Jul 22, 2016A randomized trial of individualised care versus standard care for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.OlanzapineOttawa Hospital Research InstituteClosed
Aug 18, 2015Randomised, double-blind, placebo-controlled study of apd421 (amisulpride for iv injection) as treatment of established postoperative nausea and vomiting, in…Amisulpride (ADP421)Acacia PharmaClosed
Mar 4, 20155-ht3 antagonists (antiemetics) and cardiac safetyOndansetronChild & Family Research InstituteClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Oct 14, 2015Ondansetron inhalation powderPrevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of…Luxena Pharmaceuticals, Inc.Designated
Oct 11, 20064-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl)Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.Dynogen Pharmaceuticals, Inc.Designated

Medicines Authorised in the EU

Newest first
May 26, 2016Palonosetron AccordPalonosetron · genericAccord Healthcare S.L.U.EMA ↗
May 27, 2015AkynzeoNetupitant;palonosetronHelsinn Birex Pharmaceuticals LtdEMA ↗
Apr 20, 2012SancusoGranisetronGrünenthal GmbHEMA ↗
Jan 11, 2008IvemendFosaprepitantMerck Sharp & Dohme B.V.EMA ↗
Mar 22, 2005AloxiPalonosetronHelsinn Birex Pharmaceuticals Ltd.EMA ↗
Nov 11, 2003EmendAprepitantMerck Sharp & Dohme B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.